According to Reuters, an investigational therapy called tezepelumab, an injectable therapy from AstraZenaca and Amgen, could treat a wider range of severe asthma patients than current treatments.
Findings from a mid-stage clinical trial involving 584 patients showed on Wednesday the experimental drug tezepelumab reduced the annual rate of asthma exacerbations by between 61 and 71%, depending on dose.
The results could put the first-in-class injection in a strong position in a competitive market as it heads into final-stage Phase III tests later this year or early next.
